Madison Vaccines congratulates Douglas McNeel, M.D., Ph.D., on his second Award from the Prostate Cancer Foundation.
MADISON, WI– August 24, 2017 - These awards support clinical trials with a plasmid DNA vaccine that targets PAP, an antigen specific to prostate cells. The University of Wisconsin-Madison says, "The trial will build on data from Dr. McNeel's laboratory and a previous clinical trial funded by the Prostate Cancer Foundation and Madison Vaccines, Inc., demonstrating that PD-1 inhibitor drugs can make therapeutic cancer vaccines work better."
Dr. McNeel is Professor of Medicine at the University of Wisconsin, Madison and Chief Scientific Founder and Chief Medical Officer of MVI.
Peer-Reviewed Paper Demonstrates How MVI-118 Works in Combination with Androgen Deprivation Therapy in advanced prostate cancer
MADISON VACCINES INCORPORATED APPOINTS JEFF BAILEY TO ITS BOARD OF DIRECTORS